Open Demat
Be a Partner
Samadhan
Install App
Install App

2259

500288

MOREPENLAB

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

MOREPEN LAB. LTD Share Price Update

As of the latest trading session, MOREPEN LAB. LTD is trading at ₹43.93, up by ₹0.99 or 2.30% from its previous close. The stock has moved between ₹42.70 and ₹43.99 today. Over the past year, the stock has delivered a return of -24.13%. In the last month, it has returned 14.38%.

MOREPEN LAB. LTD performance

Today’s low Today’s high
₹ 42.70 ₹ 43.99
₹ 43.71
52 week low 52 week high
₹ 33.05 ₹ 70.50
₹ 43.71
Open Price ₹ 42.70
Prev. Close ₹ 42.94
Volume (Shares) 1598321.00
Total traded value ₹ 698.62
Upper Circuit ₹ 51.52
Lower Circuit ₹ 34.36
info

Investment Returns

Over 1 Month 14.38% Over 3 Months 15.34% Over 6 Months -1.20% Over 1 Year -24.13%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

MOREPEN LAB. LTD fundamentals


  • Market cap (Cr) 2,390.70
  • P/E Ratio (TTM) 40.50
  • Beta 1.63
  • Book Value / share 21.76
  • Return on equity 9.81%
  • EPS (TTM) 1.04
  • Dividend yield 0.47%
  • Net profit/quarter (Cr) 23.50
info icon alternate text
  • Market cap (Cr) 2,383.10
  • P/E Ratio (TTM) 40.50
  • Beta 1.55
  • Book Value / share 21.76
  • Return on equity 9.81%
  • EPS (TTM) 1.04
  • Dividend yield 0.47%
  • Net profit/quarter (Cr) 23.50
info icon alternate text

MOREPEN LAB. LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 457.57
Operating Expense 430.09
Net Profit 23.50
Net Profit Margin (%) 5.13
Earnings Per Share (EPS) 0.43
EBITDA 45.82
Effective Tax Rate (%) 25.23
Particulars SEP 2025 (Values in Cr)
Revenue 369.53
Operating Expense 356.42
Net Profit 14.38
Net Profit Margin (%) 3.89
Earnings Per Share (EPS) 0.26
EBITDA 33.67
Effective Tax Rate (%) 23.80
Particulars JUN 2025 (Values in Cr)
Revenue 391.28
Operating Expense 384.02
Net Profit 8.06
Net Profit Margin (%) 2.05
Earnings Per Share (EPS) 0.15
EBITDA 23.04
Effective Tax Rate (%) 28.98
Particulars MAR 2025 (Values in Cr)
Revenue 381.94
Operating Expense 367.77
Net Profit 11.91
Net Profit Margin (%) 3.11
Earnings Per Share (EPS) 0.20
EBITDA 33.29
Effective Tax Rate (%) 31.15
Particulars DEC 2024 (Values in Cr)
Revenue 403.25
Operating Expense 377.76
Net Profit 22.69
Net Profit Margin (%) 5.62
Earnings Per Share (EPS) 0.41
EBITDA 36.46
Effective Tax Rate (%) 25.31
Particulars MAR 2025 (Values in Cr)
Revenue 1554.54
Operating Expense 1432.66
Net Profit 101.58
Net Profit Margin (%) 6.53
Earnings Per Share (EPS) 1.90
EBITDA 169.13
Effective Tax Rate (%) 26.17
Particulars MAR 2024 (Values in Cr)
Revenue 1537.59
Operating Expense 1401.18
Net Profit 110.94
Net Profit Margin (%) 7.21
Earnings Per Share (EPS) 2.17
EBITDA 174.39
Effective Tax Rate (%) 25.53
Particulars MAR 2023 (Values in Cr)
Revenue 1338.88
Operating Expense 1281.60
Net Profit 46.24
Net Profit Margin (%) 3.45
Earnings Per Share (EPS) 0.92
EBITDA 83.03
Effective Tax Rate (%) 26.64
Particulars MAR 2022 (Values in Cr)
Revenue 1449.27
Operating Expense 1333.95
Net Profit 101.06
Net Profit Margin (%) 6.97
Earnings Per Share (EPS) 2.25
EBITDA 139.36
Effective Tax Rate (%) 19.49
Particulars MAR 2021 (Values in Cr)
Revenue 1112.42
Operating Expense 1029.95
Net Profit 94.25
Net Profit Margin (%) 8.47
Earnings Per Share (EPS) 2.10
EBITDA 124.15
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 21.10
ROE % 11.78
ROCE % 14.72
Total Debt to Total Equity 0.07
EBITDA Margin 10.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 16.58
ROE % 12.08
ROCE % 16.12
Total Debt to Total Equity 0.03
EBITDA Margin 10.21
Particulars MAR 2023 (Values in Cr)
Book Value / Share 14.73
ROE % 5.81
ROCE % 8.02
Total Debt to Total Equity 0.03
EBITDA Margin 6.04
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.56
ROE % 20.27
ROCE % 21.70
Total Debt to Total Equity 0.04
EBITDA Margin 9.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.47
ROE % 25.85
ROCE % 20.94
Total Debt to Total Equity 0.21
EBITDA Margin 10.99
Particulars MAR 2025 (Values in Cr)
Book Value / Share 21.56
ROE % 9.81
ROCE % 12.79
Total Debt to Total Equity 0.06
EBITDA Margin 10.88
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.39
ROE % 13.29
ROCE % 17.08
Total Debt to Total Equity 0.03
EBITDA Margin 11.34
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.26
ROE % 6.71
ROCE % 8.78
Total Debt to Total Equity 0.03
EBITDA Margin 6.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.97
ROE % 19.38
ROCE % 20.85
Total Debt to Total Equity 0.03
EBITDA Margin 9.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.92
ROE % 24.43
ROCE % 19.57
Total Debt to Total Equity 0.21
EBITDA Margin 11.16
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 49.36
Total Assets 1778.09
Total Liabilities 1778.09
Total Equity 1186.95
Share Outstanding 54
Price to Book Ratio 2.22
Return on Assets (%) 6.63
Return on Capital (%) 9.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 52.11
Total Assets 1293.20
Total Liabilities 1293.20
Total Equity 847.22
Share Outstanding 51
Price to Book Ratio 2.42
Return on Assets (%) 7.43
Return on Capital (%) 10.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 56.30
Total Assets 1110.49
Total Liabilities 1110.49
Total Equity 752.44
Share Outstanding 51
Price to Book Ratio 1.68
Return on Assets (%) 3.48
Return on Capital (%) 4.97
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 45.97
Total Assets 1070.05
Total Liabilities 1070.05
Total Equity 578.10
Share Outstanding 47
Price to Book Ratio 3.06
Return on Assets (%) 9.50
Return on Capital (%) 17.04
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 67.89
Total Assets 858.14
Total Liabilities 858.14
Total Equity 424.29
Share Outstanding 44
Price to Book Ratio 3.60
Return on Assets (%) 11.31
Return on Capital (%) 22
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 46.33
Total Assets 1721.20
Total Liabilities 1721.20
Total Equity 1181.50
Share Outstanding 54
Price to Book Ratio 2.22
Return on Assets (%) 5.90
Return on Capital (%) 8.06
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 50.47
Total Assets 1279.30
Total Liabilities 1279.30
Total Equity 889.02
Share Outstanding 51
Price to Book Ratio 2.42
Return on Assets (%) 8.67
Return on Capital (%) 12.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 55.90
Total Assets 1105.54
Total Liabilities 1105.54
Total Equity 780.11
Share Outstanding 51
Price to Book Ratio 1.68
Return on Assets (%) 4.18
Return on Capital (%) 5.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 45.54
Total Assets 1033.26
Total Liabilities 1033.26
Total Equity 598.16
Share Outstanding 47
Price to Book Ratio 3.06
Return on Assets (%) 9.78
Return on Capital (%) 16.39
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 66.98
Total Assets 847.49
Total Liabilities 847.49
Total Equity 444.97
Share Outstanding 44
Price to Book Ratio 3.60
Return on Assets (%) 11.12
Return on Capital (%) 20.4
Particulars MAR 2025 (Values in Cr)
Net Income 155.10
Cash from Operations 69.20
Cash from Investing -321.50
Cash from Financing 299.88
Net change in Cash 10.43
Free Cash Flow 193.24
Particulars MAR 2024 (Values in Cr)
Net Income 135.41
Cash from Operations 111.48
Cash from Investing -83.30
Cash from Financing 5.20
Net change in Cash -4.72
Free Cash Flow 182.87
Particulars MAR 2023 (Values in Cr)
Net Income 55.75
Cash from Operations -74.61
Cash from Investing -46.50
Cash from Financing 143.54
Net change in Cash 5.86
Free Cash Flow -38.99
Particulars MAR 2022 (Values in Cr)
Net Income 126.70
Cash from Operations -35.30
Cash from Investing -31.67
Cash from Financing 66.33
Net change in Cash -25.58
Free Cash Flow 10.13
Particulars MAR 2021 (Values in Cr)
Net Income 98.51
Cash from Operations 52.28
Cash from Investing -70.35
Cash from Financing 47.27
Net change in Cash 27.74
Free Cash Flow 74.08
Particulars MAR 2025 (Values in Cr)
Net Income 137.58
Cash from Operations 65.14
Cash from Investing -280.42
Cash from Financing 260.46
Net change in Cash 9.12
Free Cash Flow 189.10
Particulars MAR 2024 (Values in Cr)
Net Income 148.97
Cash from Operations 114.72
Cash from Investing -83.60
Cash from Financing 0.28
Net change in Cash -5.95
Free Cash Flow 185.95
Particulars MAR 2023 (Values in Cr)
Net Income 63.04
Cash from Operations -85.84
Cash from Investing -36.19
Cash from Financing 144.19
Net change in Cash 5.88
Free Cash Flow -50.29
Particulars MAR 2022 (Values in Cr)
Net Income 125.54
Cash from Operations -44.47
Cash from Investing -22.64
Cash from Financing 66.41
Net change in Cash -25.09
Free Cash Flow 0.68
Particulars MAR 2021 (Values in Cr)
Net Income 94.24
Cash from Operations 49.31
Cash from Investing -69.08
Cash from Financing 47.46
Net change in Cash 27.68
Free Cash Flow 71.05
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.94 13.83 1.65 244.77 23.12 40.44
BLISS GVS PHARMA LTD 271.25 25.93 2.53 2869.53 114.45 280.20
CIPLA LTD. 1304.70 22.17 3.20 105391.40 1165.55 1672.20
FERMENTA BIOTECH LIMITED 282.15 9.39 2.12 830.40 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.94 30.71 4.45 244.77 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 543.55 24.36 4.24 1571.44 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8538.85 102.62 26.71 21347.13 7630.00 10653.05
BLISS GVS PHARMA LTD 271.25 36.96 2.59 2869.53 114.45 280.20

MOREPEN LAB. LTD shareholding pattern

Holding
61.5%
35.65%
1.58%
1.25%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

MOREPEN LAB. LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
43.63 1.60 redarrow
red-green-graph indicator
4 Bearish
12 Bullish
  • 5 Days 44.00
  • 26 Days 42.00
  • 10 Days 43.40
  • 50 Days 41.10
  • 12 Days 43.20
  • 100 Days 41.40
  • 20 Days 42.40
  • 200 Days 45.00
45.86 PIVOT
First Support 44.73 First Resistance 46.93 Second Support 43.66 Second Resistance 48.06 Third Support 42.53 Third Resistance 49.13
RSI 68.36 ADX 32.37 MACD 1.36 Williams % R -19.84 Commodity Channel Index (CCI) 212.50
Date 2026-05-11 Week 1770998.00 Same Day 2472181.00 Month 1531505.00
1 Year 1.62 3 Year 1.59
Over 1 Month
14.38% down
Over 1 Year
-24.13% down
Over 3 Months
15.34% down
Over 3 Years
19.10% down
Over 6 Months
-1.20% down
Over 5 Years
-5.03% down

MOREPEN LAB. LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
29 Aug 2025 0.2 Final 30 Aug 2025 Equity shares
Ex-Date Old FV NEW FV Record Date
07 Nov 2000 10.0 2.0 22 Nov 2000
06 Nov 2000 10.0 2.0 22 Nov 2000
Dividend date Dividend amount Dividend type Record date Instrument type
29 Aug 2025 0.2 Final 30 Aug 2025 Equity shares
Ex-Date Old FV NEW FV Record Date
07 Nov 2000 10.0 2.0 22 Nov 2000
06 Nov 2000 10.0 2.0 22 Nov 2000

Top Gainers

up-arrow (%)

Top Losers

up-arrow (%)

Morepen Lab share result highlights

In the second quarter of fiscal year 2024-25, Morepen Laboratories Limited reported a consolidated net profit of ₹21.26 crore, marking a 45% increase from ₹14.63 crore in the previous quarter. Revenue from operations rose by 5.2% quarter-on-quarter to ₹421.77 crore. The company's EBITDA margin improved to 12.25%, reflecting enhanced operational efficiency. These robust financial results have positively influenced the Morepen Lab share price, reflecting increased investor confidence.

Morepen Lab share annual reports

The 2023-24 annual report of Morepen Laboratories Limited provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹1,744.6 crore, registering a growth of 7.7% from the previous year. The report highlights Morepen's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Morepen Laboratories share price by showcasing the company's commitment to growth and profitability.

Morepen Lab share dividend

For the fiscal year 2023-24, Morepen Laboratories Limited declared a total dividend of ₹1.50 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Morepen Lab share price by enhancing investor confidence.

Popular FAQs

1. Who is the CEO of Morepen Lab Ltd?

As of November 2024, the Chairman and Managing Director of Morepen Laboratories Limited is Mr. Sushil Suri. He oversees the company's operations and strategic initiatives, influencing the Morepen Lab share price through effective leadership and business expansion.

 

2. When was Morepen Lab Ltd established?

Morepen Laboratories Limited was established in 1984. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Morepen Laboratories share price through its extensive operations and market presence.

 

3. What factors influence Morepen Lab Ltd share price fluctuations?

The Morepen Lab share price is influenced by various factors, including the company's financial performance, product launches, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

 

4. Is Morepen Lab debt free?

No, Morepen Laboratories Limited is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Morepen Laboratories share price.

 

5. What is the CAGR of Morepen Lab share?

Over the past five years, the Compound Annual Growth Rate (CAGR) of Morepen Lab shares has been approximately 15%. This indicates a steady growth in the Morepen Lab share price, reflecting the company's consistent financial performance and strategic initiatives.

 

6. How has the Morepen Lab share price performed over the past year?

Over the past year, the Morepen Lab share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

 

MOREPEN LAB. LTD Share Price

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.

The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.

Morepen Laboratories Limited was established in 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride.

During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.

During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency.

During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.

During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule.

During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S.

During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'.

During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.

In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.

During the year 2024, new capacities were built for manufacture of tablets wherein tablet manufacture capacity were increased to 162 units from 92.40 units in 2022-23. The capacities for capsule, oral liquid, sachet and dry syrup has also be enhanced in FY24.

The Company has developed / commercialized various new products such as Sitagliptin Hydrochloride (Anti-diabetic), Finerenone (chronic kidney disease), Cariprazine HCl (Atypical Anti-Psychotic), Resmetirom (for NASH), Bempedoic Acid (Anti-Hypercholesterolemic) & Rupatadine Fumarte (Anti-histaminic) during the year 2024-25. The newly developing molecules comprising of Sitagliptin (Anti-diabetic), Linagliptin (Anti-diabetic), Edoxaban (Anti-coagulant), and Empagliflozin (Anti-diabetic), and others, achieved a remarkable revenue growth of over 46%, further strengthening API revenue position. The Company commenced production of orthopaedic products, marking its entry into a new and promising therapeutic segment in 2025. Morepen Medipath Limited was incorporated in January 2025. Company has achieved a leadership position as one of the largest suppliers of the anti-asthmatic drug, Montelukast Sodium, produced at its USFDA-approved Masulkhana facility in 2025.

Parent organization Morepen
NSE symbol MOREPENLAB
Founded 1984
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Sushil Suri Chairman / Executive Director / M D / Promoter
Sanjay Suri WTD & Executive Director
Praveen Kumar Dutt Independent Non Exe. Director
Ranjit Khattar Independent Non Exe. Director
Savita Independent Non Exe. Director
Sharad Jain Independent Non Exe. Director
Vipul Kumar Srivastava Company Secretary
Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
-0.50%
1836.4 -9.29
down-arrow
similar-logo DIVISLAB
2.43%
6806 162.00
down-arrow
similar-logo TORNTPHARM
-1.64%
4310 -71.89
down-arrow
similar-logo CIPLA
3.20%
1333.7 41.39
down-arrow
similar-logo DRREDDY
-0.35%
1265.5 -4.50
down-arrow
similar-logo LUPIN
-0.32%
2238.1 -7.29
down-arrow
similar-logo MANKIND
2.10%
2428.9 50.00
down-arrow
similar-logo ZYDUSLIFE
0.80%
938.15 7.50
down-arrow
similar-logo AUROPHARMA
0.51%
1495.8 7.60
down-arrow
similar-logo LAURUSLABS
1.31%
1284.7 16.69
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Morepen Laboratories Ltd?

Answer Field

Morepen Laboratories Ltd share price is for NSE ₹ 43.93 & for BSE ₹ 43.95 as on May 13 2026 01:01 PM.

What is the Market Cap of Morepen Laboratories Ltd Share?

Answer Field

The market cap of Morepen Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 13 2026 01:01 PM.

What is the 52 Week High and Low of Morepen Laboratories Ltd?

Answer Field

The 52 Week High and Low of Morepen Laboratories Ltd for NSE is ₹ 70.50 and ₹ 33.05 and for BSE is ₹ 70.40 and ₹ 33.44.

What is 1 year return for Morepen Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -28.86%.

What is the P/E Ratio of Morepen Laboratories Ltd Share?

Answer Field

As on May 13 2026 01:01 PM the price-to-earnings (PE) ratio for Morepen Laboratories Ltd share is 40.50.

What is the PB ratio of Morepen Laboratories Ltd Share?

Answer Field

As on May 13 2026 01:01 PM, the price-to-book (PB) ratio for Morepen Laboratories Ltd share is 21.76.

How to Buy Morepen Laboratories Ltd Share?

Answer Field

You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Morepen Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Morepen Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Morepen Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Morepen Lab Ltd?

Answer Field

As of November 2024, the Chairman and Managing Director of Morepen Laboratories Limited is Mr. Sushil Suri. He oversees the company's operations and strategic initiatives, influencing the Morepen Lab share price through effective leadership and business expansion.

When was Morepen Lab Ltd established?

Answer Field

Morepen Laboratories Limited was established in 1984. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Morepen Laboratories share price through its extensive operations and market presence.

What factors influence Morepen Lab Ltd share price fluctuations?

Answer Field

The Morepen Lab share price is influenced by various factors, including the company's financial performance, product launches, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

Is Morepen Lab debt free?

Answer Field

No, Morepen Laboratories Limited is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Morepen Laboratories share price.

What is the CAGR of Morepen Lab share?

Answer Field

Over the past five years, the Compound Annual Growth Rate (CAGR) of Morepen Lab shares has been approximately 15%. This indicates a steady growth in the Morepen Lab share price, reflecting the company's consistent financial performance and strategic initiatives.

How has the Morepen Lab share price performed over the past year?

Answer Field

Over the past year, the Morepen Lab share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Products

arrow

Calculators

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email for any investor grievances or write to us for DP related matters.

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email | Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.